Literature DB >> 20098522

"Caseness" for depression and anxiety in a depressed outpatient population: symptomatic outcome as a function of baseline diagnostic categories.

Koen Demyttenaere1, Anne Verhaeghen, Nicolas Dantchev, Luigi Grassi, Angel L Montejo, David G S Perahia, Deborah Quail, Catherine Reed, Andre Tylee, Michael Bauer.   

Abstract

OBJECTIVE: To examine the diagnostic status of patients enrolled in the Factors Influencing Depression Endpoints Research (FINDER) study and symptomatic outcomes and baseline characteristics associated with remission 6 months after commencing antidepressant therapy.
METHOD: Status of clinically diagnosed depressed patients was based on self-rated Hospital Anxiety and Depression Scale (HADS) scores. Five diagnostic categories were defined: noncaseness, mixed anxiety-depression (subthreshold depressive and anxious symptomatology), caseness for depression, caseness for anxiety, and caseness for comorbid anxiety-depression. Assessments included the Somatic Symptom Inventory and health-related quality of life (HRQoL) using the Medical Outcomes Study 36-item Short-Form Health Survey. Remission rates (based on HADS noncaseness for both depression and anxiety) and their associations with baseline characteristics were investigated. Patients were enrolled between May 2004 and September 2005.
RESULTS: Of the 3,353 patients enrolled, 66.4% met the HADS criteria for probable depressive disorder and 74.1% met the HADS criteria for probable anxiety disorder. Somatic symptom severity (painful and nonpainful) was highest and HRQoL was lowest in the comorbid anxiety-depression group. After 6 months, remission rates were 50.2% for caseness for depression, 40.4% for caseness for anxiety, and 40.6% for caseness for comorbid anxiety-depression. A lower number of previous depressive episodes, shorter current episode duration, lower painful and nonpainful somatic symptom scores, being married, a higher educational level, and working for pay were most consistently associated with higher remission rates.
CONCLUSIONS: Physicians do not always differentiate between anxiety and depressive symptoms when making a clinical diagnosis of depression. At baseline, most enrolled patients had significant emotional depressive and anxious symptoms, as well as significant nonpainful and painful somatic symptomatology, and these factors were associated with outcome.

Entities:  

Year:  2009        PMID: 20098522      PMCID: PMC2805566          DOI: 10.4088/PCC.08m00748blu

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  34 in total

1.  Datapoints: prescription patterns for mood and anxiety disorders in a community sample.

Authors:  R Mojtabai
Journal:  Psychiatr Serv       Date:  1999-12       Impact factor: 3.084

Review 2.  The prevalence, clinical relevance, and public health significance of subthreshold depressions.

Authors:  Lewis L Judd; Pamela J Schettler; Hagop S Akiskal
Journal:  Psychiatr Clin North Am       Date:  2002-12

3.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

Review 4.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions.

Authors:  Michael Bauer; Peter C Whybrow; Jules Angst; Marcio Versiani; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2002-04       Impact factor: 4.132

Review 5.  Mixed anxiety and depression: from theory to practice.

Authors:  J P Boulenger; M Fournier; D Rosales; Y J Lavallée
Journal:  J Clin Psychiatry       Date:  1997       Impact factor: 4.384

6.  Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?

Authors:  Mark Zimmerman; Jill I Mattia; Michael A Posternak
Journal:  Am J Psychiatry       Date:  2002-03       Impact factor: 18.112

7.  Depression and anxiety associated with three pain conditions: results from a nationally representative sample.

Authors:  Lachlan A McWilliams; Renee D Goodwin; Brian J Cox
Journal:  Pain       Date:  2004-09       Impact factor: 6.961

8.  Comorbid painful physical symptoms and anxiety: prevalence, work loss and help-seeking.

Authors:  Koen Demyttenaere; Anke Bonnewyn; Ronny Bruffaerts; Ron De Graaf; Josep Maria Haro; Jordi Alonso
Journal:  J Affect Disord       Date:  2008-01-30       Impact factor: 4.839

9.  How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial?

Authors:  Gabor I Keitner; Michael A Posternak; Christine E Ryan
Journal:  J Clin Psychiatry       Date:  2003-09       Impact factor: 4.384

Review 10.  Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies.

Authors:  P Cuijpers; F Smit
Journal:  Acta Psychiatr Scand       Date:  2004-05       Impact factor: 6.392

View more
  10 in total

1.  The feasibility and effectiveness of mindfulness-based cognitive therapy for mixed diagnosis patients in primary care: a pilot study.

Authors:  Sholto R Radford; Rebecca Susan Crane; Catrin Eames; Eluned Gold; Gareth Wyn Owens
Journal:  Ment Health Fam Med       Date:  2012-09

2.  Taking the depressed "person" into account before moving into personalized or precision medicine.

Authors:  Koen Demyttenaere
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

3.  The clinical effectiveness of a cognitive behavioural therapy intervention in a work setting: a 5-year retrospective analysis of outcomes.

Authors:  David Hitt; Tayyeb Tahir; Lyndon Davies; Jo Delahay; Mark Kelson
Journal:  J Res Nurs       Date:  2018-02-05

4.  Residual sleep disturbances in patients remitted from major depressive disorder: a 4-year naturalistic follow-up study.

Authors:  Shirley X Li; Siu P Lam; Joey W Y Chan; Mandy W M Yu; Yun-Kwok Wing
Journal:  Sleep       Date:  2012-08-01       Impact factor: 5.849

5.  Course of mental symptoms in patients with stress-related exhaustion: does sex or age make a difference?

Authors:  Kristina Glise; Gunnar Ahlborg; Ingibjörg H Jonsdottir
Journal:  BMC Psychiatry       Date:  2012-03-12       Impact factor: 3.630

6.  Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine.

Authors:  Edith Schneider; Michael Linden; Harald Weigmann; Thomas Wagner; Deborah Quail; Hans-Peter Hundemer; Ulrich Hegerl
Journal:  BMC Psychiatry       Date:  2011-09-20       Impact factor: 3.630

7.  The impacts of migraine and anxiety disorders on painful physical symptoms among patients with major depressive disorder.

Authors:  Ching-I Hung; Chia-Yih Liu; Ching-Yen Chen; Ching-Hui Yang; Shuu-Jiun Wang
Journal:  J Headache Pain       Date:  2014-11-10       Impact factor: 7.277

Review 8.  The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review.

Authors:  Koen Demyttenaere; Zeno Van Duppen
Journal:  Int J Neuropsychopharmacol       Date:  2019-02-01       Impact factor: 5.176

9.  Health care costs before and after diagnosis of depression in patients with unexplained pain: a retrospective cohort study using the United Kingdom General Practice Research Database.

Authors:  Catherine Reed; Jihyung Hong; Diego Novick; Alan Lenox-Smith; Michael Happich
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-14

10.  Superoxide imbalance triggered by Val16Ala-SOD2 polymorphism increases the risk of depression and self-reported psychological stress in free-living elderly people.

Authors:  Ivo Emilio da Cruz Jung; Ivana Beatrice Mânica da Cruz; Fernanda Barbisan; Alexis Trott; Lucien J Houenou; Bárbara Osmarin Turra; Thiago Duarte; Raquel de Souza Praia; Ednea Aguiar Maia-Ribeiro; Jaqueline da Costa Escobar Piccoli; Claudia Giugliano Bica; Marta Maria Medeiros Frescura Duarte
Journal:  Mol Genet Genomic Med       Date:  2019-12-31       Impact factor: 2.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.